JP2005526808A - 炎症状態の治療においてccr−3拮抗薬として使用するためのモルホリン尿素誘導体のベンゼンスルホン酸塩 - Google Patents

炎症状態の治療においてccr−3拮抗薬として使用するためのモルホリン尿素誘導体のベンゼンスルホン酸塩 Download PDF

Info

Publication number
JP2005526808A
JP2005526808A JP2003579830A JP2003579830A JP2005526808A JP 2005526808 A JP2005526808 A JP 2005526808A JP 2003579830 A JP2003579830 A JP 2003579830A JP 2003579830 A JP2003579830 A JP 2003579830A JP 2005526808 A JP2005526808 A JP 2005526808A
Authority
JP
Japan
Prior art keywords
compound
formula
mixture
added
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003579830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526808A5 (enExample
Inventor
クック,ジョン,スペンサー
ランドン,ロバート,フィリップ
ウォルカー,アンドリュー,ジョン
ウィルキンソン,マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005526808A publication Critical patent/JP2005526808A/ja
Publication of JP2005526808A5 publication Critical patent/JP2005526808A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2003579830A 2002-03-28 2003-03-27 炎症状態の治療においてccr−3拮抗薬として使用するためのモルホリン尿素誘導体のベンゼンスルホン酸塩 Pending JP2005526808A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207432.6A GB0207432D0 (en) 2002-03-28 2002-03-28 Novel compounds
PCT/EP2003/003345 WO2003082293A1 (en) 2002-03-28 2003-03-27 Benzenesulphonate salt of a morpholine urea derivative for use as a ccr-3 antagonist in the treatment of inflammatory conditions

Publications (2)

Publication Number Publication Date
JP2005526808A true JP2005526808A (ja) 2005-09-08
JP2005526808A5 JP2005526808A5 (enExample) 2006-05-18

Family

ID=9933984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003579830A Pending JP2005526808A (ja) 2002-03-28 2003-03-27 炎症状態の治療においてccr−3拮抗薬として使用するためのモルホリン尿素誘導体のベンゼンスルホン酸塩

Country Status (22)

Country Link
US (1) US7531651B2 (enExample)
EP (1) EP1487456B1 (enExample)
JP (1) JP2005526808A (enExample)
KR (1) KR20040099375A (enExample)
CN (1) CN1642554A (enExample)
AR (1) AR039179A1 (enExample)
AT (1) ATE317698T1 (enExample)
AU (1) AU2003226761A1 (enExample)
BR (1) BR0308480A (enExample)
CA (1) CA2479912A1 (enExample)
DE (1) DE60303603T2 (enExample)
ES (1) ES2258724T3 (enExample)
GB (1) GB0207432D0 (enExample)
IL (1) IL163847A0 (enExample)
IS (1) IS7432A (enExample)
MX (1) MXPA04009456A (enExample)
NO (1) NO20044323L (enExample)
PL (1) PL372623A1 (enExample)
RU (1) RU2004126948A (enExample)
TW (1) TW200407145A (enExample)
WO (1) WO2003082293A1 (enExample)
ZA (1) ZA200407463B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335083A1 (en) * 2011-12-01 2014-11-13 Glaxo Group Limited Methods of treatment and prevention of eye diseases
FR3022142B1 (fr) 2014-06-16 2019-07-12 Universite Paul Sabatier - Toulouse Iii Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031431A1 (en) 1994-05-18 1995-11-23 Nisshin Flour Milling Co., Ltd. Novel diaminomethylidene derivative
BR9915520A (pt) 1998-11-20 2001-07-17 Hoffmann La Roche Antagonistas receptores ccr-3 derivados de pirrolidina
IL155092A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
CA2479912A1 (en) 2003-10-09
IS7432A (is) 2004-08-31
EP1487456B1 (en) 2006-02-15
EP1487456A1 (en) 2004-12-22
GB0207432D0 (en) 2002-05-08
CN1642554A (zh) 2005-07-20
TW200407145A (en) 2004-05-16
ES2258724T3 (es) 2006-09-01
AU2003226761A1 (en) 2003-10-13
RU2004126948A (ru) 2005-07-10
IL163847A0 (en) 2005-12-18
WO2003082293A1 (en) 2003-10-09
US20060089497A1 (en) 2006-04-27
BR0308480A (pt) 2005-01-18
US7531651B2 (en) 2009-05-12
PL372623A1 (en) 2005-07-25
ZA200407463B (en) 2005-10-12
DE60303603T2 (de) 2006-10-26
AR039179A1 (es) 2005-02-09
ATE317698T1 (de) 2006-03-15
NO20044323L (no) 2004-10-27
MXPA04009456A (es) 2005-01-25
DE60303603D1 (de) 2006-04-20
KR20040099375A (ko) 2004-11-26

Similar Documents

Publication Publication Date Title
US11827638B2 (en) Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
JP7416365B2 (ja) アポトーシス誘発剤
AU2023254980A1 (en) RIP1 inhibitory compounds and methods for making and using the same
KR100896838B1 (ko) 모폴린 화합물
AU2020341681A1 (en) RIP1 inhibitory compounds and methods for making and using the same
WO2021203011A1 (en) Rip1k inhibitors
CN101821260A (zh) 取代的噁唑烷酮衍生物
EA031679B1 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
US20200017498A1 (en) Small Molecule Inhibitors of the JAK Family of Kinases
JP7561497B2 (ja) 結晶性ピリミジニル-3,8-ジアザビシクロ[3.2.1]オクタニルメタノン化合物およびその使用
US20130121963A1 (en) N-phenyl-2-pyrimidineamine derivatives
EP3532470A1 (en) Oxazole derivatives for use as irak inhibitors and method for their preparation
JP2021523120A (ja) セルデュラチニブ(cerdulatinib)の固体形態
EP1487456B1 (en) Benzenesulphonate salt of a morpholine urea derivative for use as a ccr-3 antagonist in the treatment of inflammatory conditions
HK1254800A1 (zh) 2,3,4,5-四氢吡啶-6-胺衍生物
KR20190126291A (ko) 옥사진 유도체를 포함하는 약제학적 조성물 및 알츠하이머병의 치료 또는 예방에 있어서 그의 용도
JP2014501753A (ja) 3−クロロ−4[(2r)−2−(4−クロロフェニル)−4−[(1r)−1−(4−シアノフェニル)エチル]−1−ピペラジニル]−ベンゾニトリルの多形、前記多形を含む医薬組成物および使用方法、ならびにその調製方法
AU2021237686B2 (en) Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid
KR102381002B1 (ko) 벤조산 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물
HK40124049A (en) Rip1 inhibitory compounds and methods of making and using the same
HK40124048A (en) Rip1 inhibitory compounds and methods for making and using the same
HK40091929A (en) Rip1 inhibitory compounds and methods for making and using the same
KR100871272B1 (ko) 모폴린 화합물
CN116847840A (zh) 3,10-二甲氧基-5,8,13,13a-四氢-6H-异喹啉并[3,2-a]异喹啉-9-基3-氟苯磺酸酯及其盐的晶型的多晶型物
CN101137654A (zh) 奎宁环衍生物的新型盐

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100406